ProCE Banner Activity

EMBER: Phase Ia/b Study of Imlunestrant, a Next-Generation Oral SERD, in Advanced ER+/HER2- Breast Cancer

Conference Coverage

Results from the phase Ia/b EMBER trial of imlunestrant with or without everolimus or alpelisib suggest that imlunestrant may be safe and effective alone or in combination in advanced ER+/HER2- breast cancer.

Released: October 27, 2023


Provided by

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc